Stefan Buck

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children

Sylvie Retout, Stefan Buck, Jacques Gaudreault, Sébastien Jolivet et autres

Baloxavir acid (baloxavir), the active metabolite of the prodrug baloxavir marboxil, is a selective inhibitor of the influenza virus cap-dependent endonuclease. The population pharmacokinetic (popPK) profile of baloxavir in adults/adolescents has been described previously. To characterize the PK of baloxavir in patients …

ch (code pays fourni par la source)

GABriella, a Phase 2a study investigating the gamma‐secretase modulator RG6289 in individuals at risk for and at the prodromal stage of Alzheimer’s disease: baseline characteristics of the recruited participants

Rosanna Tortelli, Enrique Gaspar, Irma Triasih Kurniawan, Petr Novak et autres

Abstract Background RG6289 is a novel, potent and selective oral γ‐secretase modulator (GSM) in development for Alzheimer’s disease (AD). In the Entry‐into‐Human study in healthy volunteers, RG6289 demonstrated a favorable safety and tolerability profile, along with the anticipated pharmacodynamic effect of reducing …

ch, cn, gb (code pays fourni par la source)

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer

Simonetta Morganti, Ross J. Kusmick, Melissa E. Hughes, F. Brasó-Maristany et autres

BACKGROUND: Sacituzumab govitecan (SG) is an anti-trop2 antibody-drug conjugate (ADC) approved for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, data on effectiveness of SG and biomarkers remain limited. DNADX is a plasma-only multi-gene signature assay that identifies …

us, es, fr (code pays fourni par la source)

The translational landscape of HIV-1 infected cells reveals key gene regulatory principles

Anuja Kibe, Stefan Buck, Anne-Sophie Gribling-Burrer, Orian Gilmer et autres

Human immunodeficiency virus-1 (HIV-1) uses a number of strategies to modulate viral and host gene expression during its life cycle. To characterize the transcriptional and translational landscape of HIV-1 infected cells, we used a combination of ribosome profiling, disome sequencing and RNA …

de, fr (code pays fourni par la source)

391P Real-world activity of sacituzumab govitecan for metastatic breast cancer

Simonetta Morganti, Ross J. Kusmick, Melissa E. Hughes, F. Brasó-Maristany et autres

us, es (code pays fourni par la source)

213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC)

S. Morganti, P. Tarantino, Noah Graham, Melissa E. Hughes et autres

ADCs are effective for pts with HER2- MBC but little is known about sequencing of different ADCs. We analyzed data from pts with HER2- MBC who received ≥2 ADCs and had ≥6 months (mo) follow-up at Dana-Farber Cancer Institute between 6/2014-1/2023. ADCs …

us, es (code pays fourni par la source)

The translational landscape of HIV-1 infected cells reveals novel gene regulatory principles

Neva Caliskan, Anuja Kibe, Stefan Buck, Anne-Sophie Gribling et autres

de (code pays fourni par la source)

Supplementary Table 6 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna C. Bendell, Guy Jérusalem, Shaun Su et autres

PDF file - 62K, Summary of buparlisib pharmacokinetic parameters.

Supplementary Table 2 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna C. Bendell, Guy Jérusalem, Shaun Su et autres

PDF file - 38K, Patient disposition (full analysis set).

Supplementary Figure 1 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna C. Bendell, Guy Jérusalem, Shaun Su et autres

PDF file - 67K, Bayesian logistic regression model: dose-response curve and model inference results at the time of determination of the recommended Phase II dose.

Supplementary Table 1 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna C. Bendell, Guy Jérusalem, Shaun Su et autres

PDF file - 65K, Criteria for defining dose-limiting toxicities.

Supplementary Table 3 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna C. Bendell, Guy Jérusalem, Shaun Su et autres

PDF file - 48K, Exposure to buparlisib and trastuzumab (safety set).